Omeros announces results for narsoplimab expanded access program
Omeros (OMER) announced statistical analysis results related to the expanded access program for narsoplimab, Omeros’ ...
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) ...
Investing2d
Narsoplimab shows promise in TA-TMA survival rates
In other recent news, Omeros Corporation has announced promising results from its investigational drug, narsoplimab, in reducing mortality for patients with thrombotic microangiopathy (TA-TMA ...
FierceBiotech4d
Solid Bio's stock soars as early DMD gene therapy data beat expectations
Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...
Morningstar2d
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell ...
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003
Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin ...
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.
Solid Biosciences reports initial clinical data from INSPIRE DUCHENNE trial
Solid Biosciences (SLDB) announced initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy ...
Apellis Pharmaceuticals’ (APLS) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research report released on Thursday morning,Benzinga reports. HC Wainwright currently ...
Stocktwits on MSN3d
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?
Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...
Morningstar4d
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003
No serious adverse events (SAEs) or suspected unexpected serious adverse reactions (SUSARs) were observed, and there was no evidence of thrombotic microangiopathy (TMA), atypical hemolytic uremic ...